1186 related articles for article (PubMed ID: 23633553)
21. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
22. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
[TBL] [Abstract][Full Text] [Related]
23. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
24. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
25. GnRH agonist triggers and their use in assisted reproductive technology: the past, the present and the future.
Atkinson P; Koch J; Susic D; Ledger WL
Womens Health (Lond); 2014 May; 10(3):267-76. PubMed ID: 24956293
[TBL] [Abstract][Full Text] [Related]
26. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
27. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
28. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
[TBL] [Abstract][Full Text] [Related]
29. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
[TBL] [Abstract][Full Text] [Related]
30. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
31. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
[TBL] [Abstract][Full Text] [Related]
32. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
33. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
34. Withdrawal of GnRH agonist decreases oestradiol and VEGF concentrations in high responders.
Ding LJ; Wang B; Shen XY; Yan GJ; Zhang NY; Hu YL; Sun HX
Reprod Biomed Online; 2013 Aug; 27(2):131-9. PubMed ID: 23764202
[TBL] [Abstract][Full Text] [Related]
35. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.
Ling LP; Phoon JW; Lau MS; Chan JK; Viardot-Foucault V; Tan TY; Nadarajah S; Tan HH
Reprod Biomed Online; 2014 Sep; 29(3):392-4. PubMed ID: 25042608
[TBL] [Abstract][Full Text] [Related]
36. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
37. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
39. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
40. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study.
Vanetik S; Segal L; Breizman T; Kol S
Gynecol Endocrinol; 2018 Feb; 34(2):132-135. PubMed ID: 28933569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
